CAJ | 학술논문

目的:评价多西紫杉醇联合重组人血管内皮抑制素(恩度)二线治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应.方法:采用同期非随机对照方法,共73例晚期复发的NSCLC患者入组.28例患者接受多西紫杉醇联合恩度二线治疗(治疗组),45例患者接受多西紫杉醇单药二线治疗(对照组),每个周期行影像学检查评价疗效.结果:治疗组和对照组的有效率分别为17.9%和13.3%(P=0.850),疾病控制率分别为64.3%和53.3%(P=0.357),中位无进展生存期(PFS)分别为4个月和3个月(P=0.015),中位生存期(OS)分别为8个月和6个月(P=0.030).两组常见的毒副反应是骨髓抑制、脱发、乏力、关节酸痛,治疗组和对照组的差异无统计学意义(P＞0.05).结论:多西紫杉醇联合重组人血管内皮抑制素二线治疗既往化疗失败的晚期NSCLC,能够提高患者PFS和OS,且毒副反应无明显增加.
목적:평개다서자삼순연합중조인혈관내피억제소(은도)이선치료만기비소세포폐암(NSCLC)적료효화독부반응.방법:채용동기비수궤대조방법,공73례만기복발적NSCLC환자입조.28례환자접수다서자삼순연합은도이선치료(치료조),45례환자접수다서자삼순단약이선치료(대조조),매개주기행영상학검사평개료효.결과:치료조화대조조적유효솔분별위17.9%화13.3%(P=0.850),질병공제솔분별위64.3%화53.3%(P=0.357),중위무진전생존기(PFS)분별위4개월화3개월(P=0.015),중위생존기(OS)분별위8개월화6개월(P=0.030).량조상견적독부반응시골수억제、탈발、핍력、관절산통,치료조화대조조적차이무통계학의의(P＞0.05).결론:다서자삼순연합중조인혈관내피억제소이선치료기왕화료실패적만기NSCLC,능구제고환자PFS화OS,차독부반응무명현증가.
Objective:To evaluate the toxicity and efficacy of docetaxel plus rh-endostatin (endostar) as the second-line therapy of advanced non-small cell lung cancer(NSCLC). Methods:Seventy-three recurrently advanced NSCLC patients were enrolled. Twenty-eight patients were divided into group therapied by docetaxel plus endostar(experimental group). And 45 patients were divied into group therapied only by docetaxel(control group). Efficacy were estimated by imaging every cycle. Results:The efficacies of experimental group and control group were 17.9% and 13.3%(P=0.850). The disease control rates were 64.3% and 53.3%(P=0.357). The median progression-free survival(PFS)were 4 months and 3 months(P=0.015). The median overall survival(OS)were 8 months and 6 months(P=0.030). The most common toxicity were myelosuppression, alopecia, asthenia, joint pain. The differences of experimental group and control group were not statisticaliy significant(P＞0.05). Conclusion:PFS and OS were possibly extended by docetaxel plus endostar as second-line therapy in the advanced relaped NSCLC patients. But the toxicity were not significantly increased.